COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 61-year-old female patient received BNT162b2 (BNT162B2), on 22Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 19Apr2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 30Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 61 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Chronic bronchitis in the past" (unspecified if ongoing), notes: Chronic bronchitis in the past. Concomitant medication(s) included: TYLENOL; ZINC; AIRBORNE. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of covid-19. Reporter assessed events as non serious. The patient did not have any known allergies. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
| Vaccine Type | Manufacturer | Vaccine Name | Dose | Route | Site | Lot |
|---|---|---|---|---|---|---|
|
|
|